RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 TOPCAT: Effects of Spironolactone on CV Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 20
SP 16
OP 17
DO 10.1177/155989771320006
UL http://mdc.sagepub.com/content/13/20/16.abstract
AB In adults with heart failure and preserved ejection fraction, the mineralocorticoid receptor antagonist spironolactone did not significantly reduce the composite primary outcome of cardiovascular mortality, aborted cardiac arrest, or hospitalization for heart failure (HF) compared with placebo, but it did reduce HF hospitalizations. This article presents the results of the Treatment of Preserved Cardiac Function With an Aldosterone Antagonist [TOPCAT; NCT00094302] study.